By Fineline Cube 
Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co., Ltd. The deal grants Kexing exclusive rights to commercialise Easton’s generic apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia and Colombia. The partnership targets launch in high‑growth markets across Southeast Asia, the Middle East and Latin America.
Deal Highlights
| Item | Details |
|---|---|
| License Scope | Exclusive overseas commercialization of Easton’s apalutamide tablets in 10+ countries |
| Target Markets | Southeast Asia, Middle East, Latin America |
| Therapeutic Indication | Metastatic hormone‑sensitive prostate cancer (mHSPC) & non‑metastatic castration‑resistant prostate cancer (NM‑CRPC) |
| Regulatory Status | “Drug Registration Certificate” issued by China’s NMPA (May 2025) |
| Strategic Fit | Second high‑end prostate‑cancer asset added to Kexing’s portfolio after Enzalutamide |
Why This Matters
- Rapid Market Penetration – Kexing’s existing global sales network spans ~70 countries, enabling swift rollout of apalutamide in emerging markets.
- Portfolio Expansion – The agreement follows Kexing’s in‑licensing of Qingfeng’s Enzalutamide capsules, reinforcing its focus on premium prostate‑cancer therapies.
- Regulatory Momentum – Easton’s product has already secured NMPA approval, positioning it for expedited entry into new jurisdictions.
Company Context
- Kexing Biopharm is a Shanghai‑listed biopharmaceutical firm with a robust pipeline in oncology. It has a track record of securing approvals for multiple high‑profile drugs across diverse territories.
- Easton Biopharma specializes in generics of advanced oncology agents. Its apalutamide tablets are a second‑generation, non‑steroidal androgen‑receptor inhibitor, offering a valuable option for patients with advanced prostate cancer.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech